Uveal and Conjunctival Melanoma: Close Together-but Only Distantly RelatedJanuary 15th 2016
There has been rapid progress in the treatment of metastasis associated with cutaneous melanoma, including impressive results achieved with targeted molecular therapies and immunotherapies, and it is possible (but still unproven) that patients with metastasis from conjunctival and eyelid melanomas may benefit from these new therapies.
Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer: Is There an Optimal Succession?January 15th 2016
It remains difficult to decipher which patients are appropriate candidates for conversion therapy vs upfront surgery. Therefore, in predicting potential outcomes, several factors should be considered. Here, we will attempt to address such factors and provide insights.
Adjuvant Therapy After Resection of Metastatic Colorectal Cancer: Scant Evidence of a Curative BenefitJanuary 15th 2016
In all other settings, giving chemotherapy just to make us feel better emotionally in exchange for potential harm to the patient is not the right strategy. We need to find better treatments for this new clinical indication.
Adjuvant Therapy After Resection of Metastatic Colorectal Cancer: Clear Proof of Principle in This SettingJanuary 15th 2016
There is clear proof of principle for adjuvant therapy in patients at high risk for tumor recurrence, such as those with resected metastatic colorectal cancer. For that reason, this strategy has been largely adopted, especially using 5-FU– and oxaliplatin-based regimens, thereby mirroring the approach in resected stage III colon cancer.
Challenges and Opportunities for Immunotherapies in Gynecologic CancersJanuary 15th 2016
The advent of immunotherapy presents us with new treatment approaches in gynecologic cancers, with preliminarily promising outcomes. Multiple clinical trials are currently being conducted to better define the role of immunotherapy. Further investigation is warranted to develop and identify predictive biomarkers.
Neoadjuvant Therapy for Soft-Tissue Sarcomas-One Size Does Not Fit AllJanuary 15th 2016
Improvements in neoadjuvant therapy for soft-tissue sarcomas will require the development of more efficacious systemic therapies and, if possible, the performance of histology-specific, prospective, randomized clinical trials to advance the field.